TICKERNERD
Menu
CNSPCNSPHealthcare · Biotechnology

CNSP Stock Forecast: CNS Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$5.35
−1.47% on the day

The 1 Wall Street analysts covering CNS Pharmaceuticals, Inc. hold a median 12-month price target of $10 — +86.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$7.7M
Ticker Nerd rank
23 / 100
Median analyst target
$10
Analysts covering
1
Revenue$0.0
Operating income−$2.7M
Net income−$2.6M
Free cash flow−$3.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.1%
1M
−9.9%
YTD
+1.9%
1Y
−49.4%
From 52W high
−49.4%
From 52W low
+151.2%
$2
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CNSP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CNS Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
23 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
93
Momentum
59
Accruals
52
Quality
46
Issuance
32
Growth
27
Revisions
25
Volatility
9
Value
7

Size (93): Smaller than most of the companies we track.

Value (7): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CNSP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CNSP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$4$6$8$10$12Jan 26Apr 26Jul 26Oct 26CNSPHigh $10Median $10Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $10Median $10High $10

The green dot is the last close — the median target sits +86.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Sept 2025Maxim GroupUpgradeBuy$20
25 Mar 2025Maxim GroupDowngradeHold—
10 Sept 2024Maxim GroupUpgradeBuy$0.50
2 Feb 2021Brookline CapitalInitiatesBuy$10
24 Aug 2020Ladenburg ThalmannInitiatesBuy—
4 Dec 2019BenchmarkInitiatesSpeculative Buy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CNSP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CNSP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, CNS Pharmaceuticals, Inc. returned −49.4% against +16.2% for the S&P 500, dividends included.

CNSP vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26CNSPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CNSP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

CNS Pharmaceuticals, Inc. (CNSP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
—
Price / book
0.4×

Cheaper than 85% of US stocks

EV / EBITDA
0.7×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−106.6%

Higher than 13% of US stocks

Return on assets
−58.0%

Higher than 6% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CNS Pharmaceuticals, Inc. (CNSP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CNS Pharmaceuticals, Inc. has a market value of $7.7M and an enterprise value of −$12.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$16.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$13.4M.

  • CNS Pharmaceuticals, Inc. spent $1K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 1.5M.

  • Trailing P/E: 0.0×; forward P/E: −13.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • CNS Pharmaceuticals, Inc. employs 8 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

CNSP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CNSPCNS Pharmaceuticals, Inc.$7.7M
23
AZTRAzitra, Inc.$8.0M
40
LGVNLongeveron, Inc.$7.6M
28
SNGXSoligenix, Inc.$7.5M
27
CLGNCollPlant Biotechnologies Ltd.$7.5M
26
CURXCuranex Pharmaceuticals, Inc.$7.5M
6
SKYESkye Bioscience, Inc.$7.4M
36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CNS Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CNSP news & analysis

CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript

Seeking Alpha · 30 Sept 2026neutral

CNS Pharmaceuticals, Inc. held a shareholder/analyst call, and Seeking Alpha published the prepared remarks transcript from the event. The transcript contains the prepared statements delivered during the call.

Why it matters — The transcript gives CNSP watchers direct access to the company's prepared remarks from its shareholder/analyst call, allowing them to review management's stated position.

CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth

Accesswire · 1 Sept 2026neutral

CNS Pharmaceuticals announced that Chief Business Officer Dylan Wenke participated in a Virtual Investor "What This Means" Segment, providing an update on the company's business development strategy as part of its broader transformation. The company is working to establish a pipeline focused on oncology or neurology with best-in-class potential.

Why it matters — The update gives CNSP watchers insight into the company's business development strategy and direction as it works to build its pipeline through a transformation into oncology or neurology-focused therapies.

CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference

Accesswire · 27 Aug 2026positive

CNS Pharmaceuticals announced that it participated in the Virtual Investor "Why Now" on-demand conference. CEO Rami Levin discussed the Company's strategic transformation, highlighting its newly assembled executive leadership team, enhanced financial position following a recent financing, and a disciplined approach to evaluating differentiated assets.

Why it matters — CNSP watchers would care because the presentation provides insight into the Company's strategic direction, leadership, and financial positioning following its recent financing.

CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation

Accesswire · 12 Aug 2026positive

CNS Pharmaceuticals reported its second quarter 2026 financial results, highlighting an approximately $20.0 million cash position and an extended operating runway following an oversubscribed $22.5 million financing. The company said it is advancing its strategic transformation, introduced in March 2026, toward a diversified, high-value pipeline.

Why it matters — The earnings release confirms a strengthened balance sheet and extended cash runway supporting the company's shift from its legacy focus toward a broader pipeline strategy.

FAQ

Frequently asked questions about CNSP stock

What is the CNSP stock price forecast for 2026-2027?

The 1 Wall Street analysts covering CNS Pharmaceuticals, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CNSP stock a buy right now?

Of the 1 analysts covering CNS Pharmaceuticals, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CNS Pharmaceuticals, Inc. 23 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CNSP?

As at 8 Oct 2026, CNS Pharmaceuticals, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).

Will CNSP stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +86.9% from the last close, and Ticker Nerd's factor model ranks CNS Pharmaceuticals, Inc. 23 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CNSP stock forecast for 2030?

No analyst covering CNS Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNSP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $10 over the next 12 months.

How has CNSP stock performed over the past year?

CNS Pharmaceuticals, Inc. returned -49.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CNS Pharmaceuticals, Inc. do?

CNS Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive cancers of the brain and central nervous system.

What is the latest news on CNSP?

The most recent item we track (Seeking Alpha, 30 Sept 2026): "CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript". CNS Pharmaceuticals, Inc. held a shareholder/analyst call, and Seeking Alpha published the prepared remarks transcript from the event. The transcript contains the prepared statements delivered during the call.

Company

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive cancers of the brain and central nervous system. Its current work centers on advancing anti-cancer drug candidates designed to address high-unmet-need diseases such as glioblastoma and other malignant brain tumors. The company’s pipeline includes investigational compounds such as berubicin and other neurology and oncology assets, reflecting its emphasis on treatments that can reach and act within the central nervous system. CNS Pharmaceuticals Inc. operates in the specialized oncology segment of the pharmaceutical market, where drug development is shaped by the challenges of treating tumors protected by the blood-brain barrier. The company is based in Houston, Texas, and its role in the market is to develop novel hospital- and specialist-directed treatment options for severe brain and CNS cancers.

CEO Mr. Rami Levin M.B.A. · 8 employees · United States · https://cnspharma.com